ReleaseWire

GlobalData's clinical trial report, “Aplastic Anemia Global Clinical Trials Review, H2, 2012" provides data on the Aplastic Anemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aplastic Anemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Aplastic Anemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Huntington’s Disease Global Clinical Trials Review, H2, 2012" provides data on the Huntington’s Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Huntington’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Huntington’s Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2012" provides data on the Congestive Heart Failure (Heart Failure) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congestive Heart Failure (Heart Failure). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congestive Heart Failure (Heart Failure). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Mycobacterium Infections Global Clinical Trials Review, H1, 2012" provides data on the Mycobacterium Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycobacterium Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycobacterium Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Shock Global Clinical Trials Review, H2, 2012" provides data on the Shock clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Shock. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Shock. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Vitamin D Deficiency Disorders Global Clinical Trials Review, H2, 2012" provides data on the Vitamin D Deficiency Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vitamin D Deficiency Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vitamin D Deficiency Disorders. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Uterine Fibroids Global Clinical Trials Review, H2, 2012" provides data on the Uterine Fibroids clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Uterine Fibroids. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Uterine Fibroids. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Sarcoidosis Global Clinical Trials Review, H2, 2012" provides data on the Sarcoidosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sarcoidosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sarcoidosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, “Myelofibrosis Global Clinical Trials Review, H2, 2012" provides data on the Myelofibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myelofibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Myelofibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Internet has changed our lives in every imaginable way, and one of the most significant impacts it has had is on the way we do business. Just twenty short years ago the Internet was largely the domain of hobbyists and computer professionals. Now the Internet is a vital part of the marketing strategy of most businesses, and huge corporations are fighting for attention with more and more interesting and inventive online marketing methods.

DDos (or distributed denial of service) attacks are all too common in today’s Internet landscape. Using an army of slave computers, DDos attackers bombard servers with repeated requests, tying up the computational power and bandwidth and effectively taking them offline for legitimate users. This is a huge inconvenience to individuals, and it can also have a big financial impact on businesses.

Two fabulous homes have opened up in the Salerno at Bay Colony subdivision of Pelican Bay. Featuring views of Clam Bay, the Gulf and the Bay Colony’s nature preserves; the Salerno offers luxury living and outstanding value. Naples waterfront property is moving at significantly increased rate, and significantly increased prices for the first time since 2006. These two outstanding Salerno properties perfectly showcase the value of the last few years, while at the same representing extremely lucrative investment opportunities.

This report gives a view of the country's thermal energy market and provides forecasts to 2020. This report includes information on thermal (coal, oil and gas) installed capacity and generation. It provides information on key trends, profiles of major industry participants, information on major power plants and analysis of important deals. This along with detailed information on the regulatory framework and key policies governing the industry, provides a comprehensive understanding of the market for thermal power in the country. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Volcano Corporation (Volcano) is a medical device company, which develops, manufactures and commercializes therapy products including intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products. Its product offerings include multi-modality consoles, which offer intravascular ultrasound (IVUS), and functional measurement (FM) capabilities. The company operates its business through two business segments, namely, Medical segment and Industrial segment. The Industrial segment is operated through its wholly-owned subsidiary, Axsun Technologies, Inc., which offers micro-optical spectrometers and optical channel monitors. The company markets its products across the US, Europe, South Africa and Japan regions. It has manufacturing facilities in Rancho Cordova, California and Billerica, Massachusetts, the US. Volacano is headquartered in California, the US.

In terms of gross written premium, the Italian insurance industry is the fourth-largest insurance industry in the European region behind the UK, France and Germany. These four countries collectively account for more than XX% of the European insurance industry value in 2011. From 2008 to 2010, the French, German and Italian insurance industries all expanded rapidly, as poor overall economic performance encouraged consumers to seek the financial security associated with insurance products.

"CEO Opinions on Buyer Spend Activity in the Global Construction Industry: Survey Brief" is a new report by Timetric that analyzes C-level executives responses to understand how buyer spend activity in the construction industry are set to change in 2012-2013. This report gives you access to the annual procurement budgets, planned change in procurement expenditure, procurement expenditure by products and services, expected changes in regional supplier prices. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by company type and sizes.

"Indian Business Traveler Expectations of Key Technologies in Hotels in 2012: Survey Brief" is the result of an extensive multi-industry survey drawn from Timetric's exclusive panel of Indian business travelers. It contains in-depth analysis on Indian business traveler expectations of key technologies in hotels. This report examines new technologies which influence business travelers to choose a particular hotel. Survey results have been presented and analyzed based on age and company turnover.

Leathergoods in Mexico by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2012. This market covers travel items, such as suitcases and rucksacks; briefcases; women's handbags;, clothes accessories, such as belts and gloves; and small items, such as purses, wallets and document holders, all made predominantly of leather. It excludes items which do not contain leather or where leather is a minor part of the finished article. Market size is based on all retail sales including direct to consumer and duty free sales including sales tax. Market size for Leathergoods in Mexico is given in %, MXN, USD and units with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Mexico. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

The use of polishes, with the exception of shoe polish, decreased during the whole review period. Less time for household tasks amongst families, a high share of single-person households and use of surface care products or wipes as an alternative are all influencing polish sales negatively. In 2011, use of floor, metal and furniture polish was mainly done by older generations who are familiar with these products.

Weight management saw a positive performance in 2011, driven by consumers' desire to lose weight in order to reach their goal of having an attractive, slim body, and also because the correct weight is increasingly associated with health and wellness in the long term. Moreover, consumer demand was supported by a wide offer of high-quality products, as manufacturers are required to meet the standards imposed by the relevant European law (Direttiva Europea 2002/46) for product quality and safety.

The skin care category in 2011 consisted mainly of facial care (77% of value sales), followed by body care (20%) and then hand care (3%). These ratios have remained relatively stable throughout the review period. The market grew by 5% in current value terms to reach a size of C$1,597 million, comparing favourably to the value CAGR of 5% during the review period. Growth during the review period however has been declining since 2005 (11%) to a low of 3% in 2009. The downturn in the economy...

In 2011, retail sales of depilatories realised growth of 4% in current value terms to reach a total of C$199 million (compared to a CAGR during the review period of 7%). In terms of unit volumes, growth in 2011 was just 1%. As the growth in current value was somewhat greater than unit volume growth, this indicates that price increases drove the market in 2011. Product development and marketing (marketing support is strong for leading brands, particularly Venus from P&G and Schick from...

2011 saw the emergence of BB (beauty balm) creams in the Irish market, with Laboratories Garnier launching the first blemish balm cream in the country - Garnier Miracle Skin Perfector daily all-in-one BB cream. It is available in 50ml size and comes in two shades, priced at EUR14.99. The product differs from BB creams in other markets in that whitening or brightening claims are not made, which is hardly surprising given the typically fair complexion of Irish people. The manufacturers have opted...